GlaxoSmithKline links with CIDR for new tuberculosis treatments

Scientists at the Center for Infectious Disease Research (CIDR), the largest independent non-profit in the US focused solely on infectious disease research, partnered with the Tres Cantos Open Lab Foundation at UK pharma major GlaxoSmithKline (LSE: GSK) to advance critically-needed treatments for Mycobacterium tuberculosis (Mtb).

The research conducted through the partnership indicates that antifolates may be a candidate for continued tuberculosis drug discovery

“With tuberculosis killing 1.5 million people every year and current drugs diminishing in their effectiveness, this antifolate research is critical for finding new ways to treat TB,” said David Sherman, a professor at the Center for Infectious Disease Research.